Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE). (Real-CHOICE)
Iron Isomaltoside 1000 in Patients With Iron Deficiency or Iron Deficiency Anemia: a Multicentric, Prospective, Longitudinal, Observational Study in Switzerland.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Basel, Switzerland
- 21
-
Basel, Switzerland
- 9
-
Bern, Switzerland
- 1
-
Biel, Switzerland
- 15
-
Brugg, Switzerland
- 19
-
Gossau, Switzerland
- 18
-
Kreuzlingen, Switzerland
- 11
-
Kreuzlingen, Switzerland
- 12
-
Kreuzlingen, Switzerland
- 8
-
Liestal, Switzerland
- 5
-
Opfikon, Switzerland
- 20
-
Rheinfelden, Switzerland
- 16
-
Sankt Gallen, Switzerland
- 13
-
Sion, Switzerland
- 7
-
Spreitenbach, Switzerland
- 6
-
St. Gallen, Switzerland
- 17
-
Steinach, Switzerland
- 14
-
Wettingen, Switzerland
- 10
-
Wohlen, Switzerland
- 3
-
Zürich, Switzerland
- 2
-
Zürich, Switzerland
- 4
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Legally capable male and female patients, aged ≥ 18 years (no upper limit);
- Written informed consent of the patient with regard to the pseudonymized documentation;
- The patients are not selected by specific inclusion or exclusion criteria, but by the indication listed in the Swiss SmPC (Summary of Product Characteristics) of Monofer®;
- Decision is taken to treat the patient with IIM in accordance with the current Swiss SmPC of Monofer® and by prescription; this decision is taken prior to and independent from the inclusion into the study.
Exclusion Criteria:
- Any contraindication regarding IIM treatment as specified in the Swiss SmPC of Monofer®;
- Retrospective observation of IIM infusion;
- Current or upcoming participation in an interventional clinical trial;
- Prior IV iron treatment or transfusion within 3 months prior to enrolment;
- Instable and/or untreated comorbidities potentially hampering the observation of the primary outcome parameter of this study;
- Prisoners or persons who are compulsorily detained (involuntarily incarcerated).
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Attitude of patients towards IV iron treatment evaluated with questionnaire.
Time Frame: Change from baseline taking into account baseline (BL) and follow-up (FU) answers. Follow-up at the latest 12 weeks after observed dosing and before a potential subsequent dosing (if available based on clinical routine follow-up).
|
Rate of patients with stability or positive change in attitude. Questionnaire comprises the following questions:
|
Change from baseline taking into account baseline (BL) and follow-up (FU) answers. Follow-up at the latest 12 weeks after observed dosing and before a potential subsequent dosing (if available based on clinical routine follow-up).
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effectiveness of treatment with IIM.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Iron deficiency anemia (IDA): Hb (Hemoglobin) increase ≥ 1 g/dL.
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Effectiveness of treatment with IIM.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Iron deficiency without anemia (IDNA): Maintenance of baseline Hb-level and/or Hb above lower limit of normal (LLN).
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Attitude of patients towards IIM treatment evaluated with questionnaire.
Time Frame: Complete observation time-frame (the total observation period of this study will amount to 90 months).
|
Taking into account baseline (BL) and follow-up (FU) answers. Questionnaire comprises the following questions:
|
Complete observation time-frame (the total observation period of this study will amount to 90 months).
|
|
Attitude of physicians towards IIM and IV iron treatment evaluated with questionnaire.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Questionnaire comprises the following questions:
And:
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Patient and disease profiles at baseline.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Evaluation of kind of iron deficiency.
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Patient and disease profiles at baseline.
Time Frame: Baseline.
|
Institution of diagnosis of IDA/IDNA.
|
Baseline.
|
|
Patient and disease profiles at baseline.
Time Frame: Baseline.
|
Etiology of iron deficiency.
|
Baseline.
|
|
Patient and disease profiles at baseline.
Time Frame: Baseline.
|
Method of iron need determination.
|
Baseline.
|
|
Calculation of iron need based on IIM simplified dosing scheme.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Evaluation of dosing intensity of IIM.
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Calculation of iron need based on IIM simplified dosing scheme.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Calculated iron need.
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Calculation of iron need based on IIM simplified dosing scheme.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Determined iron need.
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Calculation of iron need based on IIM simplified dosing scheme.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Difference between administered IIM dose and calculated iron need.
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Treatment sequence before IIM.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Dose intensities of administration.
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Treatment sequence before IIM.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Dose intervals of administration.
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Reason(s) for selection of IIM.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Reasons for treatment choice of IIM in current patient populations.
Reasons could be: efficacy, safety profile, quality of life, patient's preference, physician's preference, comorbidities, convenient dosing, other.
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Treatment with IIM.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Dose intensity of administration.
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Treatment with IIM.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Mode of administration.
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Treatment with IIM.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Duration of infusion.
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Treatment satisfaction of physician and patient upon treatment.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Rate of physicians and patients with stability or positive change in satisfaction upon IIM treatment.
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Effectiveness of treatment with IIM: whole blood count changes.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Red blood cell count
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Effectiveness of treatment with IIM: whole blood count changes.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
White blood cell count
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Effectiveness of treatment with IIM: whole blood count changes.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Hemoglobin
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Effectiveness of treatment with IIM: whole blood count changes.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Hematocrit
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Effectiveness of treatment with IIM: whole blood count changes.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Platelets
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Effectiveness of treatment with IIM: total Hb increase.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Hemoglobin
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Effectiveness of treatment with IIM: serum ferritin increase.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Serum ferritin
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Effectiveness of treatment with IIM: serum ferritin increase.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Transferrin saturation (TfS)
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Effectiveness of treatment with IIM: serum ferritin increase.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Soluble transferrin receptor (sTfR)
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Effectiveness of treatment with IIM: serum ferritin increase.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Phosphate level
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Effectiveness of treatment with IIM: CRP (C-reactive protein) status.
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
CRP status.
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
|
Safety and tolerability of treatment with IIM, including frequency and severity of treatment-emergent AEs (Adverse Events) / ADRs (Adverse Drug Reactions).
Time Frame: Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Number of patients with:
|
Complete observation time-frame (the total observation period of this study per patient will amount to 3 months).
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NIS-PFM-2019-2654
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.